SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001438533-21-000021
Filing Date
2021-05-25
Accepted
2021-05-25 16:44:35
Documents
12
Period of Report
2021-05-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rtrx-20210525.htm   iXBRL 8-K 44166
  Complete submission text file 0001438533-21-000021.txt   187500

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rtrx-20210525.xsd EX-101.SCH 1989
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rtrx-20210525_lab.xml EX-101.LAB 25298
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rtrx-20210525_pre.xml EX-101.PRE 13261
5 EXTRACTED XBRL INSTANCE DOCUMENT rtrx-20210525_htm.xml XML 11214
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 21961267
SIC: 2834 Pharmaceutical Preparations